Psoriasis patients treated with interleukin-17A (IL-17A) inhibitor secukinumab demonstrated statistically significant skin clearance, according to in 2 pivotal phase 3 studies published in The New England Journal of Medicine.
Psoriasis patients treated with interleukin-17A (IL-17A) inhibitor secukinumab demonstrated statistically significant skin clearance, according to in 2 pivotal phase 3 studies published in The New England Journal of Medicine.
Secukinumab met all primary and key secondary end points in the ERASURE and FIXTURE studies, including Psoriasis Area and Severity Index (PASI) 75 and 90, and Investigator’s Global Assessment modified 2011 (IGA mod 2011) 0/1 responses at Week 12.
ERASURE (Efficacy of Response And Safety of two fixed secUkinumab Regimens in psoriasis) was a randomized double-blind, placebo-controlled, multicenter, parallel-group phase 3 study involving 738 patients with moderate-to-severe plaque psoriasis in psoriasis. In ERASUE, a higher proportion of patients treated with secukinumab 300 mg and 150 mg achieved a PASI 75 response at Week 12 compared to placebo patients, 81.6% (300 mg) and 71.6% (150 mg), versus 4.5% for placebo (P<.001). On the co-primary end point, a higher proportion of patients treated with secukinumab achieved an IGA mod 2011 0/1 response at Week 12 compared to placebo, 65.3% (300 mg) and 51.2% (150 mg), versus 2.4% for placebo (P <.001).
Additionally:
FIXTURE (the Full year Investigative eXamination of secukinumab vs. eTanercept Using 2 dosing Regimens to determine Efficacy in psoriasis) was a randomized double-blind, placebo and active controlled, multicenter, parallel-group phase 3 study involving 1,306 patients with moderate-to-severe plaque psoriasis. In FIXTURE, a higher proportion of patients treated with secukinumab 300 mg and 150 mg achieved a PASI 75 response at Week 12 compared to placebo: 77.1% (300 mg) and 67.0% (150 mg), versus 4.9% for placebo (P<.001). On the co-primary end point, a higher proportion of patients treated with secukinumab achieved an IGA mod 2011 0/1 response at Week 12 compared to placebo: 62.5% (300 mg) and 51.1% (150 mg), versus 2.8% for placebo (P<.001).
Additionally:
In ERASURE, the most common adverse events (AEs) in any treatment group including placebo (n=738) were nasopharyngitis, headache, and upper respiratory tract infection. Eighteen patients in the secukinumab 300 mg arm, 12 patients in the secukinumab 150 mg arm, and 5 patients in the placebo group discontinued the study due to AEs. Serious AEs during the entire treatment period were reported at rates (in events per 100 subject-years) of 6.3 (300 mg), 6.4 (150 mg), and 7.4 (placebo).
In FIXTURE, the most common AEs in any treatment group including etanercept and placebo (n=1,306) were nasopharyngitis, headache, and diarrhea. Fourteen patients in the secukinumab 300 mg arm, 10 patients in the secukinumab 150 mg arm, 12 patients in the etanercept arm and 3 patients in the placebo arm discontinued due to AEs. Serious AEs during the entire treatment period were reported at rates (in events per 100 subject-years) of 6.8 (300 mg), 6.0 (150 mg), 7.0 (etanercept), and 8.3 (placebo) with no clinically apparent differences in the type of serious AEs among treatment groups. There were no deaths reported although there was one death unrelated to psoriasis during the FIXTURE screening period.
Novartis sponsored the studies.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More